Efficacy and Safety of Anti-Xa Direct Oral Anticoagulants Vs. Warfarin in Patients Homozygous for Factor V Leiden and Prothrombin G20210A Mutations

Overview

Journal J Thromb Thrombolysis

Date 2025 Feb 1

PMID 39891866

Authors

Ofir Dan

Oleg Pikovsky

Tomer Kerman

Shirly Amar

Anat Rabinovich

Affiliations

Soon will be listed here.

Abstract

Factor V Leiden (FVL) and prothrombin G20210A mutation (PGM) are the most common types of inherited thrombophilia, predisposing to increased venous thromboembolism (VTE) risk. The homozygous and compound heterozygous forms of these mutations are extremely rare. While direct oral anticoagulants (DOACs) have replaced vitamin K antagonists (VKAs) as the primary treatment for VTE, data on their use in patients with high-risk hereditary thrombophilia are limited. To compare the efficacy and safety of DOACs vs. VKA in patients with high-risk hereditary thrombophilia, including FVL and PGM. This retrospective cohort study included adults with homozygous/compound heterozygous FVL and/or PGM who experienced a thrombotic event between 2000 and 2022. The primary outcome was the incidence of recurrent thrombosis in patients with high-risk inherited thrombophilia treated with DOACs versus VKAs. The secondary outcome included a comparison of rates of bleeding complications between these groups. The types of bleeding were defined according to the ISTH criteria. Of 56 patients included 28 received DOACs and 28 received VKAs. There was no significant difference in recurrent VTE rates (1/28, 3.6% DOAC group vs. 0/28, 0% VKA group) or major bleeding (1/28, 3.6% DOAC group vs. 1/28, 3.6% VKA group). This is the largest cohort of patients with high-risk hereditary thrombophilia, providing valuable insights into DOAC use in this group. The findings suggest that DOACs may represent an effective and safe alternative to VKAs. Further research is warranted to confirm these results and optimize anticoagulant management in this challenging patient group.

References

Martinelli I . Risk factors in venous thromboembolism. Thromb Haemost. 2001; 86(1):395-403. View

Castoldi E, Hezard N, Mourey G, Wichapong K, Poggi M, Ibrahim-Kosta M . Severe thrombophilia in a factor V-deficient patient homozygous for the Ala2086Asp mutation (FV Besançon). J Thromb Haemost. 2021; 19(5):1186-1199. DOI: 10.1111/jth.15274. View

Elkattawy S, Alyacoub R, Singh K, Fichadiya H, Kessler W . Prothrombin G20210A Gene Mutation-Induced Recurrent Deep Vein Thrombosis and Pulmonary Embolism: Case Report and Literature Review. J Investig Med High Impact Case Rep. 2022; 10:23247096211058486. PMC: 9016586. DOI: 10.1177/23247096211058486. View

Emmerich J, Rosendaal F, Cattaneo M, Margaglione M, De Stefano V, Cumming T . Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism--pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost. 2001; 86(3):809-16. View

Rees D, Cox M, Clegg J . World distribution of factor V Leiden. Lancet. 1995; 346(8983):1133-4. DOI: 10.1016/s0140-6736(95)91803-5. View

Rosendaal F, Reitsma P . Genetics of venous thrombosis. J Thromb Haemost. 2009; 7 Suppl 1:301-4. DOI: 10.1111/j.1538-7836.2009.03394.x. View

Rosen E, Renbaum P, Heyd J, Levy-Lahad E . High frequency of factor V Leiden in a population of Israeli Arabs. Thromb Haemost. 1999; 82(6):1768. View

Gomez-Outes A, Suarez-Gea M, Calvo-Rojas G, Lecumberri R, Rocha E, Pozo-Hernandez C . Discovery of anticoagulant drugs: a historical perspective. Curr Drug Discov Technol. 2011; 9(2):83-104. DOI: 10.2174/1570163811209020083. View

Zoller B, Svensson P, He X, Dahlback B . Identification of the same factor V gene mutation in 47 out of 50 thrombosis-prone families with inherited resistance to activated protein C. J Clin Invest. 1994; 94(6):2521-4. PMC: 330087. DOI: 10.1172/JCI117623. View

10.

Ryu J, Ramo J, Jurgens S, Niiranen T, Sanna-Cherchi S, Bauer K . Thrombosis risk in single- and double-heterozygous carriers of factor V Leiden and prothrombin G20210A in FinnGen and the UK Biobank. Blood. 2024; 143(23):2425-2432. PMC: 11830983. DOI: 10.1182/blood.2023023326. View

11.

Ho W, Hankey G, Quinlan D, Eikelboom J . Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med. 2006; 166(7):729-36. DOI: 10.1001/archinte.166.7.729. View

12.

Agnelli G, Buller H, Cohen A, Curto M, Gallus A, Johnson M . Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013; 369(9):799-808. DOI: 10.1056/NEJMoa1302507. View

13.

Schulman S, Granqvist S, Holmstrom M, Carlsson A, Lindmarker P, Nicol P . The duration of oral anticoagulant therapy after a second episode of venous thromboembolism. The Duration of Anticoagulation Trial Study Group. N Engl J Med. 1997; 336(6):393-8. DOI: 10.1056/NEJM199702063360601. View

14.

Schulman S, Kearon C, Kakkar A, Mismetti P, Schellong S, Eriksson H . Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009; 361(24):2342-52. DOI: 10.1056/NEJMoa0906598. View

15.

Skelley J, White C, Thomason A . The use of direct oral anticoagulants in inherited thrombophilia. J Thromb Thrombolysis. 2016; 43(1):24-30. DOI: 10.1007/s11239-016-1428-2. View

16.

Zuk J, Papuga-Szela E, Zareba L, Undas A . Direct oral anticoagulants in patients with severe inherited thrombophilia: a single-center cohort study. Int J Hematol. 2020; 113(2):190-198. DOI: 10.1007/s12185-020-03012-7. View

17.

Pikovsky O, Arafat M, Ovadia H, Sharoni Y, Al-Athamen K, Kanengisser-Pines B . Congenital thrombotic thrombocytopenic purpura in a large cohort of patients carrying a novel mutation in ADAMTS13 gene. Thromb Res. 2019; 185:167-170. DOI: 10.1016/j.thromres.2019.12.002. View

18.

Ageno W, Squizzato A, Wells P, Buller H, Johnson G . The diagnosis of symptomatic recurrent pulmonary embolism and deep vein thrombosis: guidance from the SSC of the ISTH. J Thromb Haemost. 2013; 11(8):1597-602. DOI: 10.1111/jth.12301. View

19.

Konstantinides S, Meyer G, Becattini C, Bueno H, Geersing G, Harjola V . 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). Eur Heart J. 2019; 41(4):543-603. DOI: 10.1093/eurheartj/ehz405. View

20.

Kaatz S, Ahmad D, Spyropoulos A, Schulman S . Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2016; 13(11):2119-26. DOI: 10.1111/jth.13140. View